Table VI.
Exon Array Results for Selected Genes of Interest from Other Studies
| SBNET vs. Normal | PNET vs. Normal | ||||
|---|---|---|---|---|---|
| Gene | Gene Name | Fold-Change | p-value | Fold-change | p-value |
| ADCY2* | Adenylate Cyclase (Brain) | +2.21 | 5.88E-05 | +1.28 | 0.1370 |
| PRKAR1A* | Protein Kinase, cAMP-dependent, Regulatory, Type I, Alpha | +1.84 | 9.19E-05 | +1.69 | 0.0020 |
| BEX1* | Brain Expressed, x-Linked 1 | +15.11 | 3.60E-08 | +2.75 | 0.0044 |
| BICD1* | Bicaudal D Homolog (Drosophila) | +1.93 | 0.0182 | +1.18 | 0.4131 |
| CHGB* | Chromogranin B (secretogranin 1) | +17.45 | 4.71E-05 | +7.38 | 0.0008 |
| CPE* | Carboxypeptidase E | +6.27 | 1.23E-08 | +4.59 | 0.0016 |
| GABRB3* | Gamma-aminobutyric Acid (GABA) A Receptor, Beta 3 | +4.01 | 6.47E-08 | +2.68 | 0.0031 |
| SCG2* | Secretogranin II | +2.61 | 4.52E-05 | +7.98 | 0.0011 |
| SCG3* | Secretogranin III | +7.20 | 1.06E-05 | +5.80 | 0.0016 |
| ACTG2† | Actin, gamma 2, Smooth Muscle, Enteric | −1.55 | 0.3933 | +1.02 | 0.9551 |
| GREM2† | Gremlin 2 | −1.49 | 0.1147 | −1.27 | 0.0196 |
| REG3A† | Regenerating Islet-Derived 3 Alpha | −9.18 | 2.15E-05 | −2.82 | 0.4280 |
| TUSC2† | Tumor Suppressor Candidate 2 | +1.05 | 0.7133 | −1.57 | 0.0065 |
| RUNX1† | Runt-Related Transcription Factor 1 | −1.03 | 0.8191 | +1.19 | 0.5596 |
| TPHl† | Tryptophan Hydroxylase 1 | +17.71 | 7.82E-05 | +2.04 | 0.1128 |
| TGFBR2† | Transforming Growth Factor, Beta Receptor II | −1.45 | 0.1322 | −1.19 | 0.4957 |
| CDH6† | Cadherin 6, Type 2, K- Cadherin (Fetal Kidney) | +5.62 | 1.15E-06 | +2.68 | 0.0068 |
| ECM1‡ | Extracellular Matrix Protein 1 | +2.86 | 0.0136 | −1.02 | 0.9086 |
| VMAT1‡ | Solute Carrier Family 18 (Vesicular Monoamine), Member 1 | +22.06 | 3.40E-06 | −1.30 | 0.1677 |
| LGALS4‡ | Lectin, Galactoside-Binding, Soluble, 4 | −3 15 | 0.0038 | −1.99 | 0.1649 |
| TSC2§ | Tuberous Sclerosis 2 | +1.12 | 0.4872 | −1.24 | 0.0386 |
| SSTR2§ | Somatostatin Receptor 2 | +1.49 | 0.0118 | +1.62 | 0.0680 |
| FGF13§ | Fibroblast Growth Factor 13 | +1.41 | 0.0003 | +1.03 | 0.8247 |
| FEV‡ | FEV (ETS Oncogene Family) | +2.15 | 0.0071 | −1.18 | 0.0263 |
| ADCY2‡ | Adenylate Cyclase (Brain) | +2.21 | 5.88E-05 | +1.28 | 0.1370 |
| NR4A2‡ | Nuclear Receptor Subfamily 4, Group A, Member 2 | +1.13 | 0.6564 | −2.17 | 0.1000 |
| GADD45b‡ | Growth Arrest and DNA- Damage-Inducible, Beta | −1.08 | 0.5842 | −2.25 | 0.0016 |
| CD302‖ | Type Lectin Domain Family 13, Member A | NA | NA | NA | NA |
| PPWD1‖ | Peptidylprolyl Isomerase Domain and WD Repeat Containing 1 | +1.14 | 0.5971 | +1.61 | 0.0030 |
| ABHD14B‖ | Abhydrolase Domain Containing 14B | −1.09 | 0.3084 | −1.35 | 0.0064 |
Gray coloration indicates the primary site upon which the study noted focused. Non-shaded areas for comparison purposes from the other primary site.
Drozdov I, Svejda B, Gustafsson BI, Mane S, Pfragner R, Kidd M, et al. Gene network inference and biochemical assessment delineates GPCR pathways and CREB targets in small intestinal neuroendocrine neoplasia. PLoS One. 2011;6:e22457.
Edfeldt K, Bjorklund P, Akerstrom G, Westin G, Hellman P, Stalberg P. Different gene expression profiles in metastasizing midgut carcinoid tumors. Endocr Relat Cancer. 2011; 18:479–489.
Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28:245–255.
Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, et al. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer. 2008;15:243–256.
Posorski N, Kaemmerer D, Ernst G, Grabowski P, Hoersch D, Hommann M, et al. Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases. Clin Exp Metastasis. 2011;28:637–647.